The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

Inclusion Criteria: * ECOG performance status 0-2 * Life expectancy of greater than 12 months * No prior history of esophageal surgery or endoscopic treatment of dysplasia * No prior exposure to sorafenib * Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer) * Age 18 years. * Patients must have adequate organ and marrow function as defined below: * hemoglobin: 8.5 g/dL * absolute neutrophil count: 1,500/L * platelets: 100,000/L (greater than 35,000/L without transfusion for less than 1 X the institutional upper limit of normal) * creatinine less than 1.5 X institutional upper limit of normal * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * A patient will be withdrawn from the study if any of the following events occur while on therapy: * Interruption of scheduled therapy for greater than 7 days * Intolerable adverse effects which are judged by the investigator to be either physically or psychologically detrimental to the patient * Patient decision to discontinue treatment * Pregnancy * Patient non-compliance with therapy administration * Grade 3 or 4 NCI-CTC toxicity attributable to sorafenib * Treatment with other chemotherapeutic or investigational anti-neoplastic drugs * Disease progression * HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib.Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.